This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (105)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Metabolic Diseases  • Nutritional and Metabolic Disorders, Other  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Alexander Tenenbaum, MD, PhD; Michael Motro, MD; Enrique Z. Fisman, MD; David Tanne, MD; Valentina Boyko, MS; Solomon Behar, MD

Arch Intern Med. 2005;165:1154-1160.

Background  A consistent relationship between metabolic syndrome (MS) and myocardial infarction (MI) has been demonstrated. We evaluated the effect of bezafibrate retard, a fibric acid derivative, on the incidence of MI in patients with MS enrolled in the Bezafibrate Infarction Prevention (BIP) study.

Methods  Patients who displayed at least 3 of the following 5 risk factors were considered to have MS: (1) a fasting glucose level of 110 mg/dL (6.11 mmol/L); (2) a triglyceride level of 150 mg/dL (1.70 mmol/L); (3) a high-density lipoprotein cholesterol level less than 40 mg/dL (<1.04 mmol/L) in men or less than 50 mg/dL (<1.30 mmol/L) in women; (4) a systolic blood pressure of 130 mm Hg or diastolic blood pressure of 85 mm Hg; and (5) a body mass index of 28.0 kg/m². The study sample for this post hoc subgroup analyses comprised 1470 patients aged 42 to 74 years. The patients received either 400 mg of bezafibrate retard (740 patients) or placebo (730 patients) once a day. The mean follow-up period was 6.2 years for events and 8.1 years for mortality data.

Results  New MI was recorded in 193 patients: 82 (11.1%) of the 740 patients in the bezafibrate group vs 111 (15.2%) of the 730 patients in the placebo group (P = .02). Bezafibrate was associated with a reduced risk of any MI and nonfatal MI with hazard ratios (HRs) of 0.71 (95% confidence interval [CI], 0.54-0.95) and 0.67 (95% CI, 0.49-0.91), respectively. The cardiac mortality risk tended to be lower in patients taking bezafibrate (HR, 0.74; 95% CI, 0.54-1.03). In 575 patients with augmented features of MS (4-5 risk factors), the remarkable strengthening of cardiac mortality reduction when taking bezafibrate (HR, 0.44; 95% CI, 0.25-0.80) should be noted.

Conclusion  Bezafibrate reduces the incidence of MI in patients with MS during long-term follow-up.

Author Affiliations: Cardiac Rehabilitation Institute (Drs Tenenbaum, Motro, and Fisman) and Bezafibrate Infarction Prevention Study Coordinating Center (Drs Tanne and Behar and Ms Boyko), Neufeld Cardiac Research Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

The Other Side of the Bezafibrate Infarction Prevention Trial Data
James McCormack and Peter Loewen
Arch Intern Med. 2005;165(20):2431-2432.
EXTRACT | FULL TEXT  

The Other Side of the Bezafibrate Infarction Prevention Trial Data—Reply
Alexander Tenenbaum, Michael Motro, Enrique Z. Fisman, David Tanne, Valentina Boyko, and Solomon Behar
Arch Intern Med. 2005;165(20):2432.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?
Bitzur et al.
Diabetes Care 2009;32:S373-S377.
FULL TEXT  

Dyslipidemia and cardiovascular risk: the importance of early prevention
Miller
QJM 2009;102:657-667.
ABSTRACT | FULL TEXT  

Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor {alpha}-Independent Mechanism
Nakajima et al.
Mol. Pharmacol. 2009;75:782-792.
ABSTRACT | FULL TEXT  

Long-term Benefit of High-Density Lipoprotein Cholesterol-Raising Therapy With Bezafibrate: 16-Year Mortality Follow-up of the Bezafibrate Infarction Prevention Trial
Goldenberg et al.
Arch Intern Med 2009;169:508-514.
ABSTRACT | FULL TEXT  

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Scott et al.
Diabetes Care 2009;32:493-498.
ABSTRACT | FULL TEXT  

PPAR-{alpha} activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway
Bulhak et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;296:H719-H727.
ABSTRACT | FULL TEXT  

Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents
Shen and Ordovas
Clin. Chem. 2009;55:256-264.
ABSTRACT | FULL TEXT  

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart et al.
Diabetes and Vascular Disease Research 2008;5:319-335.
ABSTRACT  

Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT | FULL TEXT  

HDL-cholesterol modulation and its impact on the management of cardiovascular risk
Ferns and Keti
Ann Clin Biochem 2008;45:122-128.
ABSTRACT | FULL TEXT  

From individual risk factors and the metabolic syndrome to global cardiometabolic risk
Despres et al.
Eur Heart J Suppl 2008;10:B24-B33.
ABSTRACT | FULL TEXT  

Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
Goldenberg et al.
J Am Coll Cardiol 2008;51:459-465.
ABSTRACT | FULL TEXT  

Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter and Rye
Arterioscler. Thromb. Vasc. Bio. 2008;28:39-46.
ABSTRACT | FULL TEXT  

Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Steiner
Diabetes and Vascular Disease Research 2007;4:368-374.
ABSTRACT  

The role of fenofibrate in clinical practice
Zambon and Cusi
Diabetes and Vascular Disease Research 2007;4:S15-S20.
ABSTRACT  

Hypertriglyceridemia: its etiology, effects and treatment
Yuan et al.
CMAJ 2007;176:1113-1120.
ABSTRACT | FULL TEXT  

Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level
Hiuge et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:635-641.
ABSTRACT | FULL TEXT  

Fibrates after the FIELD study: some answers, more questions
Wierzbicki
Diabetes and Vascular Disease Research 2006;3:166-171.
ABSTRACT  

Multitherapy for diabetes
Menard and Ardilouze
CMAJ 2006;175:1247-1247.
FULL TEXT  

Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
Gilde et al.
J Am Coll Cardiol 2006;48:A24-A32.
ABSTRACT | FULL TEXT  

C-Reactive Protein as a Predictor of Incident Ischemic Stroke Among Patients With Preexisting Cardiovascular Disease
Tanne et al.
Stroke 2006;37:1720-1724.
ABSTRACT | FULL TEXT  

Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes
McQueen
Evid. Based Med. 2006;11:86-86.
FULL TEXT  

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Tenenbaum et al.
Arch Intern Med 2006;166:737-741.
ABSTRACT | FULL TEXT  

Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease
Koga et al.
Eur Heart J 2006;27:817-823.
ABSTRACT | FULL TEXT  

Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism?
Barter and Rye
Circulation 2006;113:1553-1555.
FULL TEXT  

The Other Side of the Bezafibrate Infarction Prevention Trial Data
McCormack and Loewen
Arch Intern Med 2005;165:2431-2432.
FULL TEXT  

The Other Side of the Bezafibrate Infarction Prevention Trial Data--Reply
Tenenbaum et al.
Arch Intern Med 2005;165:2432-2432.
FULL TEXT  

2nd International Symposium on Triglycerides and HDL: Metabolic syndrome
Bloomgarden
Diabetes Care 2005;28:2577-2584.
FULL TEXT  

JournalScan
Malik
Heart 2005;91:1118-1120.
FULL TEXT